Basic Information
Pamorelin Powder for Suspension for Injection 11.25 mg per vial
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Regulatory Information
SIN14324P
March 11, 2013
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XL02AE04
Company Information
ORIENT EUROPHARMA PTE LTD
ORIENT EUROPHARMA PTE LTD
Active Ingredients
Strength: 11.25 mg
Detailed Information
Contraindications
**Contraindications** Pamorelin is contraindicated in patients with known hypersensitivity to triptorelin, GnRH (Gonadotropin releasing hormone), other GnRH agonist analogues or to any of the excipients of Pamorelin. Pamorelin is contraindicated in patients with spinal cord compression secondary to prostate cancer metastases. Pamorelin is contraindicated during pregnancy and lactation period. Pamorelin is contraindicated in patients with unexplained vaginal bleedings.
Indication Information
**Therapeutic indications** Pamorelin 3.75 mg, 11.25 mg, and 22.5 mg is indicated for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Pamorelin 3.75 mg, 11.25 mg, and 22.5 mg are indicated as concomitant to and following radiotherapy in patients with high-risk localized or locally advanced prostate cancer. Pamorelin 3.75 mg is indicated for the treatment of endometriosis. Pamorelin 3.75 mg is indicated for the pituitary down-regulation in the context of assisted reproduction technology. Pamorelin 22.5 mg is indicated for the treatment of central precocious puberty (CPP) in children of 2 years of age and older with an onset of CPP before 8 years in girls and 10 years in boys.